Business Description
ACME Laboratories Ltd
ISIN : BD0491ACME00
Total Employee Number:
9,301Compare
Compare
Traded in other countries / regions
ACMELAB.Bangladesh IPO Date
2016-06-07Description
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.11 | |||||
Equity-to-Asset | 0.47 | |||||
Debt-to-Equity | 0.85 | |||||
Debt-to-EBITDA | 4.27 | |||||
Interest Coverage | 2.19 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 1.83 | |||||
Beneish M-Score | -1.49 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 15.4 | |||||
3-Year EBITDA Growth Rate | 14 | |||||
3-Year EPS without NRI Growth Rate | 16.1 | |||||
3-Year Book Growth Rate | 7.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 88.06 | |||||
9-Day RSI | 81.19 | |||||
14-Day RSI | 76.24 | |||||
3-1 Month Momentum % | 4.65 | |||||
6-1 Month Momentum % | 9.29 | |||||
12-1 Month Momentum % | 5.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.2 | |||||
Quick Ratio | 0.65 | |||||
Cash Ratio | 0.12 | |||||
Days Inventory | 254.71 | |||||
Days Sales Outstanding | 43.59 | |||||
Days Payable | 10.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 4.03 | |||||
Dividend Payout Ratio | 0.37 | |||||
3-Year Dividend Growth Rate | 9.7 | |||||
Forward Dividend Yield % | 4.03 | |||||
5-Year Yield-on-Cost % | 3.72 | |||||
Shareholder Yield % | 4.46 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 41.45 | |||||
Operating Margin % | 16.51 | |||||
Net Margin % | 6.53 | |||||
EBITDA Margin % | 18.26 | |||||
FCF Margin % | 8.09 | |||||
OCF Margin % | 13.74 | |||||
ROE % | 7.32 | |||||
ROA % | 3.36 | |||||
ROIC % | 6.6 | |||||
3-Year ROIIC % | 12.02 | |||||
ROC (Joel Greenblatt) % | 9.65 | |||||
ROCE % | 13.6 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 9.24 | |||||
PE Ratio without NRI | 9.24 | |||||
Shiller PE Ratio | 8.19 | |||||
Price-to-Owner-Earnings | 11.83 | |||||
PEG Ratio | 1.05 | |||||
PS Ratio | 0.61 | |||||
PB Ratio | 0.66 | |||||
Price-to-Tangible-Book | 0.66 | |||||
Price-to-Free-Cash-Flow | 7.47 | |||||
Price-to-Operating-Cash-Flow | 4.39 | |||||
EV-to-EBIT | 7.93 | |||||
EV-to-EBITDA | 7.11 | |||||
EV-to-Revenue | 1.3 | |||||
EV-to-FCF | 15.85 | |||||
Price-to-GF-Value | 0.69 | |||||
Price-to-Projected-FCF | 1.58 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.93 | |||||
Price-to-Graham-Number | 0.46 | |||||
Earnings Yield (Greenblatt) % | 12.6 | |||||
FCF Yield % | 13.39 | |||||
Forward Rate of Return (Yacktman) % | 5.62 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ACME Laboratories Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil BDT) | 30,462.951 | ||
| EPS (TTM) (BDT) | 9.41 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -0.13 | ||
| 3-Year Sortino Ratio | -0.24 | ||
| Volatility % | 20.78 | ||
| 14-Day RSI | 76.24 | ||
| 14-Day ATR (BDT) | 1.684444 | ||
| 20-Day SMA (BDT) | 82.455 | ||
| 12-1 Month Momentum % | 5.91 | ||
| 52-Week Range (BDT) | 68.6 - 88.7 | ||
| Shares Outstanding (Mil) | 211.6 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ACME Laboratories Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ACME Laboratories Ltd Stock Events
| Event | Date | Price (BDT) | ||
|---|---|---|---|---|
| BDT 3.500000 Cash Dividend | 2025-11-19 | 74.00 (+0.00%) | ||
| BDT 3.500000 Cash Dividend | 2024-11-21 | 77.20 (+0.00%) |
Show
Entries
ACME Laboratories Ltd Frequently Asked Questions
What is ACME Laboratories Ltd(DHA:ACMELAB)'s stock price today?
The current price of DHA:ACMELAB is BDT86.90. The 52 week high of DHA:ACMELAB is BDT88.70 and 52 week low is BDT68.60.
When is next earnings date of ACME Laboratories Ltd(DHA:ACMELAB)?
The next earnings date of ACME Laboratories Ltd(DHA:ACMELAB) is .
Does ACME Laboratories Ltd(DHA:ACMELAB) pay dividends? If so, how much?
The Dividend Yield %  of ACME Laboratories Ltd(DHA:ACMELAB) is 4.03% (As of Today), Highest Dividend Payout Ratio of ACME Laboratories Ltd(DHA:ACMELAB) was 0.52. The lowest was 0.25. And the median was 0.42. The  Forward Dividend Yield % of ACME Laboratories Ltd(DHA:ACMELAB) is 4.03%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on ACME Laboratories Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers